US/UK/Canada

Share

Contacts

  • BIOINVENT
    Sölvegatan 41 223 70 LUND
    +46 46 286 85 50
    +46 46 211 08 06
    http://www.bioinvent.com

    • Quotes

    FDA approval of the Phase I/IIa study of BI-1808 is another important milestone for BioInvent as we continue to broaden our exciting pipeline of anti-cancer antibodies. TNFR2 is increasingly attracting interest as revealed by the recent deals in the field. The development of BI-1808 is supported by an impressive set of preclinical data and is one of three BioInvent lead candidates in clinical development.
    Martin Welschof, CEO BioInvent International
    The data on BI-1607 are very exciting and provide proof-of-concept of its ability to enhance anti-cancer immunity, illustrated by its ability to boost activity and overcome resistance to CTLA-4-based therapy. We are looking forward to advancing BI-1607 into clinical development and expect to submit a clinical trial application during H2 2021. It will be BioInvent’s fourth drug candidate in clinical development, further demonstrating the strength and productivity of our technology platform.
    Martin Welschof, CEO
    Pick a time period -
    Tags ( Active)

    BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin’s lymphoma patients

    · Responses in 6 out of 9 patients evaluated provide exciting evidence that BI-1206 has the potential to restore activity of rituximab in non-Hodgkin’s lymphoma patients who have relapsed after treatment with rituximab · Long-lasting complete responses observed in two patients beyond 12 months · Key opinion leader (KOL) call to discuss results today, January 28, at 5.30 p.m. CET (11:30 a.m. ET)   Lund, Sweden – January 28, 2021 – BioInvent International AB (“BioInvent”) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-

    Annual Report 2017

    Lund, Sweden – 3 April 2018 – BioInvent International AB (OMXS: BINV) today announces that the Annual Report for 2017 now is available at the company’s website, www.bioinvent.com.     Notes to editors: About BioInventBioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company’s clinical programmes are BI-1206, currently in a Phase I/II for non-Hodgkin’s lymphoma and chronic lymphatic leukaemia and TB- 403, in cooperation with Oncurious, currently in Phase I/II for

    BioInvent enter process development and manufacturing collaboration with Alligator

    Lund, Sweden – 8 July 2016, – BioInvent International (BINV) today announces that it has signed an agreement with Alligator Bioscience AB to provide process development and manufacturing services for Alligator’s new bispecific antibody, ADC-1015. “The agreement with Alligator to manufacture its new bispecific antibody ADC-1015 speaks to our leading expertise when it comes to manufacturing of antibodies. Our manufacturing facility will be upgraded during 2016 which includes installation of a Single Use Bioreactor (SUB). This enables delivery according to timelines defined by Alligator.

    Management's shareholding after completion of the rights issue

    Lund, Sweden – 15 June, 2015 – BioInvent International AB (publ) (OMXS:BINV) has previously announced that members of BioInvent’s management and key personnel have, in addition to existing holdings, purchased subscription rights and subscribed for new shares corresponding to a total of 2.8 per cent of the shares offered in the rights issue completed in May 2015. Following the completion of the rights issue Management’s changes in shareholdings are presented. +----------------------------+----------+--------+----------------------+|Management's shareholding |Before the| Changes|After

    BioInvent Interim Report 1 January – 30 September 2014

    Additional milestone payment and progress in prioritised projectsThird quarter 2014, July – September · Net sales for July – September 2014 amounted to SEK 11 (7.8) million. · Earnings after tax for July – September 2014: SEK -10 (-15) million. · Earnings after tax per share for July – September before and after dilution: SEK -0.09 (-0.19). ·  Cash flow from current operations and investment activities for July – September 2014: SEK -3.9 (-19) million. Nine-month report 2014, January – September · Net sales for January – September 2014 amounted to SEK 45 (32) million.

    BioInvent Interim Report 1 January – 30 June 2014

    Milestone payments and sale of product rights bring profit in second quarterSecond quarter 2014, April - June · Net sales for April – June 2014 amounted to SEK 32 (12) million. · Earnings after tax for April – June 2014: SEK 3.7 (-9.4) million. · Earnings after tax per share for April – June before and after dilution: SEK 0.04 (-0.13). · Cash flow from current operations and investment activities for April – June 2014: SEK -25 (-37) million. Half year results 2014, January – June · Net sales for January – June 2014 amounted to SEK 34 (24) million. · Earnings after

    BioInvent granted US patent for the F.I.R.S.T.™ antibody screening technology

    Lund, Sweden – 11 November, 2013 – BioInvent International AB (OMXS: BINV) today announces that it has has been granted a US patent for its antibody and concomitant target discovery technology F.I.R.S.T.™. Traditional drug discovery methods involve the identification of drugs candidates that bind to known disease targets. The F.I.R.S.T.™ technology is a novel and unique discovery method, which allows for antibodies and disease targets to be identified simultaneously. BioInvent has used F.I.R.S.T.™ successfully in several proprietary discovery projects and offers F.I.R.S.T.™ as well as

    BioInvent receives clinical milestone in partner program

    Lund, Sweden – 8 July 2013 - BioInvent International (OMXS:BINV) today announces that it will receive a milestone payment in connection with a partner’s start of a phase I clinical study using a n-CoDeR® antibody. BioInvent’s pipeline of external drug programmes consists of another seven antibodies in pre-clinical development of which additional candidates are expected to enter clinical trials in 2013. Cristina Glad, CEO of BioInvent, commented: “The advancement by one of our partners of an n-CoDeR® antibody into the clinic is an important step forward for BioInvent. Progress in our

    BioInvent Presents Positive Data for BI-505 at International Myeloma Congress

    Lund, Sweden – 4 April 2013 – BioInvent International AB (OMXS:BINV) announce that the previously communicated positive results from a phase I trial of BI-505 is presented today at The International Myeloma Workshop in Kyoto, Japan. At the same meeting, preclinical data is also presented which demonstrate significantly enhanced efficacy when approved myeloma drugs are combined with BI-505. BI-505 is a human antibody directed against ICAM-1 and is developed for the treatment of multiple myeloma. The results from the phase I study of BI-505 in patients with advanced multiple myeloma are

    BioInvent Interim Report 1 January – 30 September 2012

    New focusThe company has decided to focus the business with the goal of achieving self-financing of operations before external costs for new clinical trials. Proprietary development of novel antibody therapeutics will mainly concentrate on the field of oncology and thus gain a clear focus on a specific indication. During the period from July to October the number of full-time employees was reduced from 89 to 48. In July 2012 the number of full-time employees was reduced by 21. After completion of union negotiations in October, it was decided that the number would be reduced by another

    BioInvent focuses its business

    Lund, Sweden – 2 October 2012 – BioInvent International AB (OMXS:BINV) announces today that the company has decided to focus its operations with the aim of achieving self-financing of the business before external costs for future new clinical studies. Its development of proprietary antibody drugs will concentrate primarily on developing new cancer drugs, resulting in a clear indication focus. The company currently has five agreements with major companies based on products from the antibody library, n-CoDeR®. The company will increase the efforts to create new n‑CoDeR agreements for clinical

    Anti-cancer activity of BI-505 demonstrated in animal model

    Results presented at American Society of HematologyLund, Sweden–12 December 2011 – BioInvent International AB (OMXS: BINV) announced today that new preclinical data has been presented on its BI-505 programme that demonstrates anti-cancer activity in multiple myeloma and beneficial effect on bone density. The results were presented at the American Society of Hematology (ASH) Annual Meeting, San Diego, USA on Sunday 11 December 2011. The study was conducted by researchers at the University of Utah, Salt Lake City, USA under the direction of Professor Guido Tricot. Compared to untreated

    BI-505 data at American Society of Hematology

    Lund, Sweden – 2 December 2011 – Researchers at the University of Utah, Salt Lake City, under the direction of professor Guido Tricot, will present data involving BI-505 at the annual meeting of American Society of Hematology, which takes place in San Diego, December 10-13, 2011. The abstract will be discussed during an oral session on Sunday, December 11, 2011. The abstract can be retrieved at www.hematology.org under the Abstract section.Abstract #2914, The effect of ICAM-1 Antibody Therapy in the SCID-Hu Mouse Model Using Primary Myeloma Cells. Session: 652, Myeloma –

    BioInvent holds Capital Markets Day in Stockholm

    Detailed review of BioInvent’s programmes, including its lead products, BI-204 (cardiovascular disease) and TB-402 (anti-Factor VIII)Lund, Sweden–8 November 2011 – BioInvent International AB (OMXS: BINV) will hold its first Capital Markets Day for investors, analysts and media today. The event will be hosted by Svein Mathisen, CEO, and Sten Westerberg, VP IR of BioInvent. They will be supported by members of the senior team, including Steven Glazer MD, Senior Vice President, Development, Martin Wiles, Senior Vice President, Business Development, Björn Frendéus, Vice President,

    BioInvent Interim Report 1 January – 30 June 2011

    · A private placement of SEK 136 million before transaction costs was completed in June at a share price of SEK 22.30. About twenty investors, mainly institutions, participated with the majority of the new shares subscribed by international investors.  · In May Roche initiated a phase Ib/II study with drug candidate TB-403 (RG7334) in patients with glioblastoma multiforme. BioInvent and its partner Thrombogenics received EUR 4 million in a milestone payment from Roche. In March Roche initiated a phase Ib study in patients with primary liver cancer.  · First patient in a phase IIb

    Annual General Meeting in BioInvent International AB

    The shareholders of BioInvent International AB (publ), reg no 556537-7263, are hereby invited to attend the Annual General Meeting (the “AGM”) to be held at 4 p.m., Thursday March 24, 2011 at Edison Park, Emdalavägen 16 in Lund, Sweden. N.B. New place of meeting! A.                         NOTICE OF ATTENDANCE Shareholders who wish to attend the AGM must: (i)                be recorded in the printout of the share register maintained by Euroclear Sweden AB (“Euroclear”), as of Friday March 18, 2011; and (ii)               notify the company of their intention to attend the

    BioInvent extends antibody collaboration with Japanese pharmaceutical partner

    Lead candidate for inflammation to progress into preclinical developmentLund, Sweden – 21 December 2010 – BioInvent International AB (OMXS: BINV) today announced that it has signed an agreement to extend its existing collaboration with an undisclosed Japanese pharmaceutical group. The extended collaboration comes as the Japanese company intends to take a lead candidate into preclinical development, within the area of inflammation. This lead candidate was discovered using BioInvent’s n-CoDeR antibody library.  Under the extended agreement BioInvent will do stable cell line and process

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe